#United States #Baltimore #Neurotechnology #CraniUS #Oray Boston

CraniUS Therapeutics Adds Oray Boston Jr. to Board of Directors

CraniUS Therapeutics LLC, a promising player in the neurotechnology sector, has recently announced the appointment of Oray B. Boston Jr. to its Board of Directors. This strategic move comes as the company aims to leverage Mr. Boston's extensive experience in medical devices and pharmaceuticals to enhance its mission in developing innovative solutions for neurological diseases.

A Heavyweight in Neurotechnology

Oray Boston brings over 35 years of leadership expertise, having held significant positions at Johnson & Johnson. Most notably, he served as the Worldwide President of Trauma, Extremities, Craniomaxillofacial, Sports, and Animal Health at DePuy Synthes. His role required steering a vast global business portfolio, providing him with invaluable insights into both developed and emerging markets. His proven track record in commercialization and product strategy is seen as a critical asset for CraniUS Therapeutics, especially as they progress towards their clinical and commercial milestones.

Prior to his time at DePuy Synthes, Mr. Boston was the President of Global Biosurgery for Ethicon and held various leadership roles across sales and franchise strategies. Throughout his career, he has been instrumental in launching large-scale products and navigating the complexities of international markets, especially in highly regulated healthcare environments. Moreover, his current involvement on the Board of Directors for Keurig Dr Pepper further underscores his vast and versatile experience in managing successful commercial strategies.

Driving Innovation in Drug Delivery

CraniUS is on the cusp of transforming the landscape for neurological treatment with its revolutionary device, NeuroPASS™. This investigational, fully-implantable system is designed to bypass the blood-brain barrier, allowing for direct and localized drug delivery to brain tissues. The company is set on advancing its multi-product platform that promises to enhance therapeutic options across a range of neurological disorders.

Mr. Boston expressed his enthusiasm for the new role, stating, "CraniUS is advancing a differentiated approach to drug delivery for neurological diseases. I look forward to supporting the company as it progresses toward clinical and commercial milestones." His insight into craniofacial device innovation and global commercialization will be vital as the company executes its development strategy.

Dr. Chad Gordon, Founder and Executive Chairman of CraniUS Therapeutics, echoed this sentiment, stating that Oray's depth of experience will complement the existing diverse expertise within their Board. This aligns with their strategy of navigating towards commercialization while ensuring robust growth opportunities.

The Future of CraniUS Therapeutics

As the company prepares for the future, Mr. Boston's unique perspective on managing both cranial devices and pharmaceutical platforms will undeniably bolster the Board's capability to guide commercialization strategies effectively. Mike Maglin, Chief Executive Officer at CraniUS, added that Oray's contributions will maximize the company’s growth-related opportunities, particularly in the rapidly evolving field of neurotechnology.

CraniUS Therapeutics is headquartered in Baltimore, Maryland, where it collaborates with leading experts in various fields including neurosurgery, drug delivery, implant design, and device engineering. With the introduction of Oray Boston into its leadership structure, CraniUS is undoubtedly positioning itself on an upward trajectory aimed at revolutionizing the treatment of debilitating neurological conditions. As the company marches toward its ambitious commercialization goals, the healthcare community watches closely, hopeful for innovations that can make a tangible impact.